![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Entrada Therapeutics Inc | NASDAQ:TRDA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.08 | 0.56% | 14.25 | 13.47 | 17.50 | 14.56 | 13.98 | 14.34 | 742,761 | 21:07:26 |
By Colin Kellaher
Entrada Therapeutics on Wednesday said the U.S. Food and Drug Administration declined to lift the clinical hold on a planned study of ENTR-601-44 as a potential treatment of Duchenne muscular dystrophy.
The Boston clinical-stage biopharmaceutical company said it is disappointed by the FDA's decision, citing the strength of a data package it submitted to the agency after the hold was implemented late last year.
Entrada said the information it submitted to the FDA supported the initiation of a Phase 1 study in the U.K. in September, and that it has completed dosing for the first and second cohorts in the study, with plans to announce data in the second half of 2024.
Entrada said it continues to plan for the global development of ENTR-601-44, adding that it will re-engage the FDA to discuss its next steps in due course.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 22, 2023 07:39 ET (12:39 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Entrada Therapeutics Chart |
1 Month Entrada Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions